tag:blogger.com,1999:blog-42018081943015987662012-02-10T19:04:39.190-08:00Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.comBlogger751100tag:blogger.com,1999:blog-4201808194301598766.post-46685346248860066872008-08-12T17:55:00.000-07:002008-08-12T17:57:28.507-07:00

CALGARY, AB, --- August 12, 2008 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today that the U.S. National Cancer Institute (NCI), part of the National Institutes of Health, has started enrolment in a Phase 2 clinical trial for patients with metastatic melanoma using systemic administration of REOLYSIN®, Oncolytics’ proprietary formulation of the human reovirus. The

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com13tag:blogger.com,1999:blog-4201808194301598766.post-8852038294022728382008-07-30T05:53:00.000-07:002008-07-30T06:04:53.307-07:00

CALGARY, July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its financial results and highlights for the three and six month periods ended June 30, 2008."Oncolytics experienced a strong second quarter with the reporting of durable clinical responses to REOLYSIN® combination therapy treatment in refractory head and neck cancer patients,"

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-84519420605640126302008-07-17T10:59:00.000-07:002008-07-17T11:02:40.109-07:00

Ok, so this is a few days late, but I think most of you should have known about this already.Monday July 14, 4:22 pm ET- Company to Host Conference Call to Update Clinical Program -CALGARY, July 14Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has now enrolled and treated 200 cancer patients in clinical studies with Reolysin®, its proprietary formulation of

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-47889163017715675872008-06-24T14:38:00.000-07:002008-06-24T14:42:49.897-07:00

Interesting article worth checking out from McClatchy Newspapers.Viruses aren't always the bad guys. Sure, they can cause colds, measles, AIDS and other miseries. But with some tinkering, these tiny organisms may become a new and better way to treat cancer....researchers are working with a harmless virus that sits in the lungs and intestines of most people. It's called a "reovirus," short for

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-62734230943232152612008-06-19T23:47:00.000-07:002008-06-19T23:51:14.682-07:00

CALGARY, June 20 - Oncolytics Biotech Inc. ("Oncolytics") announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-59616669428963143592008-06-12T11:27:00.000-07:002008-06-12T11:30:00.425-07:00

CALGARY, June 12 - Oncolytics Biotech Inc., announced today that Dr. Brad Thompson, President and CEO of Oncolytics, will participate in two separate presentations at the BIO 2008 International Convention.Dr. Thompson is scheduled to provide a corporate overview of the Company on Tuesday, June 17th at 3:30 p.m. PT at the BIO Business Forum.On Wednesday, June 18th at 4:00 p.m. PT, Dr. Thompson is

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-70013851409631128412008-06-10T21:11:00.000-07:002008-06-10T21:21:03.948-07:00

CALGARY, June 10 - Oncolytics Biotech Inc. ("Oncolytics") announced today that patient enrolment has started in a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal and fallopian tube cancers using concurrent intravenous (IV) and intraperitoneal (IP) administration of REOLYSIN®, Oncolytics' proprietary formulation of the human reovirus. The National Cancer Institute (NCI),

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-63574677582399962112008-06-09T22:11:00.000-07:002008-06-09T22:16:58.049-07:00

Oncolytics Biotech, Inc. filed Form F-10 with the United States Securities and Exchange Commision. See the text here.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-34635345918759942492008-06-09T22:07:00.000-07:002008-06-09T22:10:15.309-07:00

CALGARY, Canada, June 5 -- Oncolytics Biotech Inc. ("Oncolytics") announced today that that it has started patient enrolment in a Phase II clinical trial using intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The principal investigator is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-60734831622714660592008-06-02T00:39:00.000-07:002008-06-02T00:49:11.953-07:00

CALGARY, Canada, June 2/Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim results of a Phase II study of intravenous REOLYSIN® in patients with sarcomas metastatic to the lung were presented yesterday at the American Society of Clinical Oncology (ASCO) annual meeting. The presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-34891956810454269812008-05-28T18:15:00.000-07:002008-05-28T18:17:23.898-07:00

CALGARY, May 26/Dr. Matt Coffey, Chief Scientific Officer of Oncolytics Biotech Inc. will present an update on the clinical development of Reolysin at the 4th Canadian Gene Therapy and Vaccines Symposium on Tuesday, May 27 at 10:00 a.m. (ET). The symposium is being held at the National Research Council's Biotechnology Research Institute in Montreal, Quebec on May 26th and 27th, 2008.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-38261267194389443792008-05-28T18:13:00.000-07:002008-05-28T18:15:05.316-07:00

CALGARY, May 23/Oncolytics Biotech Inc. today announced it has been granted Canadian Patent 2,360,833 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders." The claims describe the use of one or more recombinant reoviruses to treat Ras-mediated proliferative disorders."This patent provides the Company with additional patent protection for the use of reovirus compositions for

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-92062589379121104032008-05-28T18:10:00.000-07:002008-05-28T18:13:15.452-07:00

CALGARY, May 22/Oncolytics Biotech Inc. announced today that it has successfully transferred cGMP production for REOLYSIN® at the 40-litre batch size to SAFC Pharma(TM), a Division of Sigma-Aldrich Corporation. This follows the successful scale-up from 20 litres to 40 litres announced by the Company last year. Yields at the 40-litre scale should provide sufficient doses to support future

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-59149827108633813432008-05-28T18:09:00.000-07:002008-05-28T18:10:41.887-07:00

A few older news releases.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-32276158372582299662008-05-20T07:23:00.000-07:002008-05-20T07:24:52.073-07:00

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,374,752 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders." The claims cover pharmaceutical compositions which comprise various recombinant reoviruses."This patent provides the Company with additional patent protection for reovirus compositions in the

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-38015942263291124162008-05-16T10:28:00.000-07:002008-05-16T10:50:52.149-07:00

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that an abstract covering interim results of a Phase II study of intravenous REOLYSIN® in patients with sarcomas metastatic to the lung is available on the American Society of Clinical Oncology (ASCO) website at www.asco.org and on the Oncolytics website at www.oncolyticsbiotech.com. The abstract is entitled "A Phase II Study of

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-50140429040700893832008-05-14T06:49:00.000-07:002008-05-14T06:54:05.729-07:00

CALGARY, AB, --- May 14, 2008 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a Phase II clinical trial using intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-49930139618851384362008-05-09T12:45:00.000-07:002008-05-09T12:48:24.956-07:00

CALGARY, May 9 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has begun patient enrolment in a clinical trial using intravenous administration of REOLYSIN® in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com1tag:blogger.com,1999:blog-4201808194301598766.post-50366474647773133302008-05-05T06:27:00.000-07:002008-05-05T06:32:43.334-07:00

Oncolytics Biotech Inc. announced today that its 2008 Annual and Special Meeting of the Shareholders will be held on Wednesday, May 7, 2008 at 9:00 a.m. (ET) at the Yale Club of New York City, 50 Vanderbilt Ave, New York.Following the business portion of the meeting, Dr. Brad Thompson, President and CEO of Oncolytics, will discuss recent progress in developing REOLYSIN® as a potential cancer

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com1tag:blogger.com,1999:blog-4201808194301598766.post-39338028406572227562008-05-03T16:52:00.000-07:002008-05-03T16:58:16.365-07:00

The 2008 Annual and Special Meeting webcast will be held this Wednesday, May 7th at 9:30 am ET. Listen to the webcast here.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com2tag:blogger.com,1999:blog-4201808194301598766.post-31736276650522692752008-04-30T18:22:00.000-07:002008-04-30T18:32:47.775-07:00

Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) today announced its financial results and highlights for the three month period ended March 31, 2008.“We are currently enrolling or recruiting patients in a total of nine clinical trials, four exploring the use of REOLYSIN® as a monotherapy, and five exploring the use of REOLYSIN® in combination with a variety of chemotherapies, immune

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-80999014736507502232008-04-23T10:57:00.000-07:002008-04-23T11:16:17.669-07:00

Oncolytics Biotech announced the publication of the first study that shows that the reovirus directly activates human dendritic cells, and that reovirus-activated dendritic cells stimulate innate killing by natural killer cells and T cells. This suggests a new potential role for T cells in oncolytic virus-induced local tumor cell death.Read the press release here or below.Oncolytics Biotech Inc.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-7618226838609028272008-04-17T15:05:00.000-07:002008-04-17T15:14:57.173-07:00

Viral Therapy in Treating Patients With Metastatic MelanomaRATIONALE: Viral therapy may be able to kill tumor cells without damaging normal cells.PURPOSE: This phase II trial is studying the side effects and how well viral therapy works in treating patients with metastatic melanoma.OBJECTIVES:PrimaryTo assess the antitumor effect of wild-type reovirus (Reolysin®), in terms of tumor response rate

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-17701958219257577812008-04-16T18:13:00.000-07:002008-04-16T18:17:13.554-07:00

LOS ANGELES (April 15, 2008) – A common, naturally occurring virus that attacks cancer cells but appears to be harmless to normal cells is being studied as a possible treatment for malignant, highly aggressive and deadly brain tumors called gliomas. Researchers at Cedars-Sinai Medical Center are among a few in the United States evaluating this experimental therapy.Read more here.For more

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-35947954983929048002008-04-16T06:39:00.000-07:002008-04-16T06:42:05.436-07:00

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that Prof. Alan Melcher and his research group at St. James's University Hospital in Leeds, U.K. published the results of their work in the April 10 online issue of Gene Therapy. The paper is entitled "Inflammatory Tumour Cell Killing by Oncolytic Reovirus for the Treatment of Melanoma."The investigators showed that

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-67494389655998120052008-04-15T13:07:00.000-07:002008-04-15T13:10:23.156-07:00

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that an oral presentation by Dr. Chandini Thirukkumaran of the Tom Baker Cancer Centre, Calgary, entitled "Targeting Multiple Myeloma with Oncolytic Viral Therapy" was presented today at the American Association for Cancer Research (AACR) Annual Meeting. The meeting is being held in San Diego, California from April 12-16, 2008.The

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-5735236079122254352008-04-15T12:23:00.000-07:002008-04-15T13:10:58.990-07:00

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that a poster presentation by Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research entitled “Radiation in Combination with Reolysin for Pediatric Sarcomas” was presented today at the American Association for Cancer Research (AACR) Annual Meeting. The meeting is being held in San Diego, California from April 12-16, 2008.“The

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-89283309039512214022008-04-14T10:25:00.000-07:002008-04-14T10:30:25.460-07:00

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient enrolment in the dose escalation portion of its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with advanced cancers including head and neck, melanoma, lung and ovarian."The preliminary results from this

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-78059260436221875102008-04-11T10:56:00.000-07:002008-04-11T11:57:55.704-07:00

This study is currently recruiting participants.RATIONALE: Viral therapy may be able to kill tumor cells without damaging normal cells.PURPOSE: This phase I/II trial is studying the side effects and best dose of viral therapy in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that did not respond to platinum chemotherapy.OBJECTIVES:PrimaryTo

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-87987750093508423122008-04-09T09:09:00.000-07:002008-04-11T12:04:51.726-07:00

CALGARY, AB, --- April 9, 2008 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) today announced positive interim results from its U.K. combination REOLYSIN® and carboplatin/paclitaxel trial. Dr. Kevin Harrington of The Institute of Cancer Research, London, and the principal investigator for the trial, presented the results today at The 5th Annual Conference of the British Society

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-89096951000380323542008-04-09T00:21:00.000-07:002008-04-11T12:31:41.610-07:00

Click here to see the entire report.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com2tag:blogger.com,1999:blog-4201808194301598766.post-87616643127457499522008-03-26T08:46:00.000-07:002008-03-26T09:07:31.276-07:00

Some of you may have already seen this, but here is the schedule for the Oncolytics Biotech related presentations with excerpts from the abstracts.Abstract Number: 906Session Title: Therapeutic Implications of Oncogenic Pathways 1Presentation Title: Replication of mutant strains of oncolytic reovirus in different cell linesPresentation Start/End Time: Sunday, Apr 13, 2008, 1:00 PM - 5:00

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-4383107391637786322008-03-19T20:08:00.000-07:002008-03-19T20:15:54.620-07:00

Article from the UT Health Science Center website detailing the honor awarded Dr. Giles which was mentioned in my previous post.SAN ANTONIO — The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio announced today that Francis J. Giles, M.D., M.B., F.R.C.P.I., F.R.C.Path, received the Medtronic Award at the National University of Ireland Galway

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-73681419847082210592008-03-19T07:39:00.000-07:002008-04-11T12:09:25.575-07:00

Interview with Doctor Frank GilesFrom the Irish Medical Timeshttp://www.imt.ie/news/2008/03/viruses_set_to_kill_cancer.htmlby Gary CullitonGalway-born Dr Frank Giles is responsible for cancer care in a much larger population than the entire island of Ireland. He heads up functional clinical cancer services for many millions of people in Texas as Chief of the Division of Haematology and Medical

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-74790353324885907512008-03-18T06:34:00.000-07:002008-04-11T12:10:34.831-07:00

CALGARY, March 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,344,711 entitled "Use of Adenoviruses Mutated in the VA Genes for Cancer Treatment." The claims describe methods of treating cancer using adenoviruses that are modified to selectively replicate in cancer cells that have an activated Ras

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-16936112933981152132008-03-17T15:56:00.000-07:002008-04-11T12:25:54.822-07:00

CALGARY, March 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported today that Dr. Kevin Harrington and his research group at The Institute of Cancer Research, London, U.K. published the results of their work characterizing immune system responses to administration of intravenous REOLYSIN® in a Phase I clinical trial. The paper, entitled "

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-20040919470666777672008-03-13T14:02:00.000-07:002008-03-13T14:10:50.019-07:00

CALGARY, AB, --- March 13, 2008 -Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that two abstracts covering preclinical work with reovirus are available today on the American Association for Cancer Research (AACR) website at www.aacr.org, and on the Oncolytics website at www.oncolyticsbiotech.com. Both presentations are scheduled to be delivered at the AACR Annual Meeting in San Diego

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com1tag:blogger.com,1999:blog-4201808194301598766.post-48436056715851934662008-03-11T18:29:00.000-07:002008-03-11T18:32:41.294-07:00

Materials from the February 28-29, 2008 Oncology Biologics Development Primer (OBDP) were released today. You can find the meeting materials here, and Dr. Matt Coffey's slides here.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-52774207137007252642008-03-11T13:25:00.000-07:002008-03-11T13:44:03.445-07:00

CALGARY, AB, --- March 10, 2008--- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the BioSquare 2008 Conference on Thursday, March 13, 2008. The event is being held at the Congress Center in Basel, Switzerland from March 12-14, 2008.For more information on BioSquare go here.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-66571513627097137522008-03-09T12:34:00.000-07:002008-03-09T12:41:31.745-07:00

Check out Deborah Foster's "When the Family has Cancer" page for an update on Kenny, a patient in Oncolytics Biotech's phase II program.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-19483306450169605892008-03-08T12:11:00.000-08:002008-03-08T12:33:29.860-08:00

CALGARY, AB, March 6, 2008 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) (“Oncolytics” or the “Company”) today reported its financial results for the year ended December 31, 2007.“2007 was our most productive year to date, marking a significant expansion of the Company’s clinical trial program for REOLYSIN® with Phase II studies and combination drug therapy studies being expanded and

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-60558491667954996192008-02-23T08:32:00.000-08:002008-02-23T08:35:56.826-08:00

CALGARY, Alberta, --- February 21, 2008 – Dr. Matt Coffey, Chief Scientific Officer of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate as an invited speaker in a session entitled “Case Studies in Gene Therapies” at the Oncology Biologics Development Primer (OBDP) conference on Friday, February 29, 2008. The OBDP was developed by the International Society for Biological Therapy

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-31333814929406176392008-02-19T21:06:00.000-08:002008-02-19T21:09:16.087-08:00

"Coincidence or phenomena? The reovirus is Mother Nature's own cancer-killer." Provocative headlines from PharmExec.com.Read the full article here.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-69296131966514842172008-02-09T15:28:00.000-08:002008-02-09T15:57:21.054-08:00

Kenny, a patient in the San Antonio trials, checks in with some new information:...this last time, I also had a PET scan (my first one). The results showed “no metabolic activity”, which “suggests” that there may not be any active cancer cells anywhere. Medically speaking, there seems to be little evidence that I have cancer any more...Exciting indeed. I encourage everyone to keep Kenny in your

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-81664608285442724432008-02-06T15:34:00.000-08:002008-02-06T15:35:58.846-08:00

CALGARY, Alberta, --- February 6, 2008Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate as an invited speaker as part of a panel discussion entitled “Breaking Down the Barriers to New Neuro-Oncology Drugs” at the 10th Annual Bio CEO & Investor Conference 2008 on Monday, February 11 at 9:30 a.m. (ET). The conference, which is expected to

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-68396558202889737242008-02-04T01:43:00.000-08:002008-04-11T12:30:52.403-07:00

CALGARY, Canada, February 4 /PRNewswire/Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported today that Dr. Kevin Harrington and his research group at The Institute of Cancer Research, London, U.K. published the results of their work testing combination treatment schedules of reovirus and radiation in human and murine tumour cells in vitro and in vivo. The paper, entitled "

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-59545297440027698832008-01-31T07:14:00.000-08:002008-01-31T07:15:34.652-08:00

CALGARY, AB, --- January 31, 2008 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today that it has met the initial criteria to proceed to full enrolment in its U.S. Phase II trial to evaluate the intravenous administration of REOLYSIN® in patients with various sarcomas that have metastasized to the lung. According to the trial protocol, to proceed to full enrolment of

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com1tag:blogger.com,1999:blog-4201808194301598766.post-4635762952482730782008-01-29T23:57:00.000-08:002008-01-30T00:00:40.247-08:00

CALGARY, AB --- January 29, 2008 - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) (“Oncolytics”) has been granted Canadian Patent 2,408,251 entitled “Clearance of Neoplastic Cells from Mixed Cellular Compositions using Viruses.” The claims describe methods of selectively removing cancer cells ex vivo from blood stem cells and other organs using various viruses including modified vaccinia

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-54929924047898592962008-01-28T12:57:00.000-08:002008-01-28T13:35:41.624-08:00

Siccing a Virus on the Deadliest CancersThe February 4th edition of BusinessWeek magazine includes a feature on Oncolytics Biotech, Inc. and the NCI ovarian trials called: Siccing a Virus on the Deadliest Cancers. I think a mention in such a high profile magazine speaks to the importance of these trials and the investigation of Reolysin with ovarian cancer.Read the article here.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-50423160514902527552008-01-23T10:06:00.000-08:002008-01-23T10:22:22.866-08:00

For those of you who missed this like I did, read the article from business week here regarding the NCI Phase I/II. I think of all the trials thus far this is the one I'm most personally interested in following.Don't forget to scroll down for this morning's press release.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-42404948513502434552008-01-23T07:07:00.000-08:002008-01-23T07:10:54.663-08:00

1/23/2008 9:43:18 AM ET CALGARY, AB --- January 23, 2008 - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) (“Oncolytics”) has been granted Canadian Patent 2,508,238 entitled “Reovirus for the Treatment of Neoplasia.” The claims describe using various human reoviruses to treat cancers that have inactivated or deleted PKR, a host cellular protein responsible for preventing virus replication within

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-66048329049571948142008-01-03T07:38:00.000-08:002008-01-03T07:49:31.477-08:00

CALGARY, AB, --- January 3, 2008 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today that the U.S. National Cancer Institute (NCI) has filed a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers using concurrent systemic and intraperitoneal administration of

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com1tag:blogger.com,1999:blog-4201808194301598766.post-62795520850553209722007-12-21T09:39:00.000-08:002007-12-21T09:46:55.485-08:00

CALGARY, AB, --- December 21, 2007Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) has completed patient enrolment in its Phase Ia/Ib U.K. clinical trial investigating the intratumoural delivery of REOLYSIN® in combination with radiation to treat patients with advanced cancers. A total of 23 patients received a range of two to six intratumoural doses of REOLYSIN® at escalating

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com1tag:blogger.com,1999:blog-4201808194301598766.post-16443599643980441022007-11-29T06:14:00.000-08:002007-11-29T06:16:55.804-08:00

CALGARY, AB, --- November 29, 2007 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced that Dr. Matt Coffey, Chief Scientific Officer of Oncolytics, is scheduled to deliver a presentation on Wednesday, December 5, 2007 entitled “Large Scale Production Process for the Oncolytic Agent REOLYSIN® (Human Reovirus)” at the Informa Life Sciences’ 3rd Annual Vaccine Production

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-63455447685631798672007-11-28T10:12:00.000-08:002007-11-28T10:40:22.826-08:00

11/27/2007 7:08:59 AM ETCALGARY, AB --- November 27, 2007 - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) (“Oncolytics”) today announced that it has been granted U.S. Patent 7,300,650 entitled “Reovirus for the Treatment of Neoplasia.” The claims describe methods of using the reovirus to treat cancers that have inactivated PKR, whether the PKR is inactivated by mutation of Ras or by other

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-40760515609379772582007-11-24T14:03:00.000-08:002007-11-24T14:10:52.295-08:00

From Biotechnology FocusBy Shawn LawrenceFor decades scientists, researchers and even big pharma companies have all tried in vain to find the cure for cancer. While the concept of a magic bullet to beat the disease has long been abandoned, one company may have in fact uncovered a promising new treatment through the use of something that most people actually go out of their way to avoid: a virus.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-16688015785062092862007-11-14T01:16:00.000-08:002007-11-19T00:15:51.587-08:00

The following is posted for informational purposes only and so that the text can be searched and referenced. Although I have made every effort to ensure accuracy, no warranties are made or implied. I encourage everyone to listen to the original source.0:00Speaking on behalf of Oncolytics, Brad Thompson, CEO and President. Thanks very much. We trade both on NASDAQ and on Toronto, so if

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-16202882058707459842007-11-08T10:16:00.000-08:002007-11-08T10:32:46.739-08:00

CALGARY, AB,November 8, 2007Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the BIO-Europe 2007 13th Annual International Partnering Conference on Tuesday, November 13, 2007. The event is being held at the CCH-Congress Center, Hamburg, Germany from November 12-14, 2007.About Oncolytics Biotech

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-43729128955403568502007-10-31T21:05:00.000-07:002008-03-17T21:21:27.958-07:00

Oncolytics Biotech Scientific Advisory Board Member, Dr. Alan J. Tuchman, appointed Board Director for Duska Therapeutics, Inc. See article here.Oncolytics Biotech Inc. insiders buy shares. See article here.Researchers say biologic therapy may kill cancer without hurting patient. See the video here, or read the article here.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-89482940315001427272007-10-30T06:43:00.000-07:002007-10-30T07:13:02.515-07:00

Edited. Read the complete report here.CALGARY, AB, --- October 30, 2007Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) today announced its financial results and highlights for the three and nine-month periods ended September 30, 2007.Third Quarter Highlights• Announced positive interim results from a U.K. Phase Ia/1b combination REOLYSIN® and radiation trial for patients with

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-76954332901107568072007-10-25T01:07:00.000-07:002007-10-25T01:19:05.674-07:00

The following is posted for informational purposes only and so that the text can be searched and referenced. Although I have made every effort to ensure accuracy, no warranties are made or implied. I encourage everyone to listen to the call here.Transcript of Brad Thompson's Conference Call made October 24, 2007.Good afternoon, ladies and gentlemen. And welcome to Oncolytics Biotech’s clinical

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com1tag:blogger.com,1999:blog-4201808194301598766.post-61223974823069762722007-10-24T06:54:00.000-07:002007-10-24T07:00:56.709-07:00

From the website.10/24/2007 2:00:00 AM ETCALGARY, AB, --- October 24, 2007 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) today announced that a poster presentation covering interim results from a U.K. Phase Ia/Ib combination REOLYSIN®/radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented today at the AACR-NCI-EORTC International

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-5502582540821354742007-10-23T15:27:00.000-07:002007-10-23T16:43:00.304-07:00

From the website.10/23/20075:13:16 PM ETOncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN® in Combination with Cyclophosphamide CALGARY, AB, --- October 23, 2007 -Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-75879560733317816752007-10-22T07:16:00.000-07:002007-10-22T18:32:56.289-07:00

The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics gets underway in a few hours. Abstracts were released this morning, the following is the abstract in interest to Oncolytics Biotech followers: B81 A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN®) in combination with

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-80371273250032238822007-10-19T14:54:00.000-07:002007-10-19T15:18:27.081-07:00

What a day and what a perfect close to two straight weeks of high volume and stock appreciation. Looks like somebody really wanted to get a hold of some ONCY before the start of the AACR-NCI-EORTC International Conference. Looking forward to the news.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-68289874422983959252007-10-18T21:10:00.000-07:002007-10-18T21:47:29.782-07:00

The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics will begin this Monday, October 22, 2007 at the Moscone Convention Center in San Francisco, California. Scheduled to be presented at the conference, which runs through October 26th, will be interim results of the combination Reolysin and radiation trial.View the program here.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-22768580308894847542007-10-17T00:47:00.000-07:002007-10-17T02:01:05.367-07:00

The following is posted for informational purposes only and so that the text can be searched and referenced. Although I have made every effort to ensure accuracy, no warranties are made or implied. I encourage everyone to listen to the presentation here.BIO InvestorForum 2007Ms. Mary Anne DillahuntyVice President, Intellectual PropertyOncolytics Biotech Inc.October 11, 2007.(Slide 1)Thank you.

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com1tag:blogger.com,1999:blog-4201808194301598766.post-82204648836638101722007-10-15T14:19:00.000-07:002007-10-15T14:27:54.081-07:00

Regional facility hopes to attract top mindsBy William LinThe Ottawa CitizenMonday, October 15, 2007An Ottawa family has donated $1 million to the Ottawa Regional Cancer Foundation, a windfall it hopes will help attract three leading researchers and advance the testing of cancer-killing viruses.The money will streamline clinical trials for a cutting-edge cancer therapy using oncolytic viruses,

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-53738257501309813132007-10-15T01:22:00.000-07:002007-10-15T01:27:58.487-07:00

Thanks everybody for visiting my site. I am more than just a little surprised to see how many people stop by everyday. By the report that I receive, Oncolytics.blogspot.com is one of my most popular blogs, and I guess there's a lot more interest in Oncolytics than I thought. I was away for most of last week, which turned out to be an interesting one for ONCY. We saw some significant volume

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-16816543455069320522007-10-08T12:50:00.000-07:002007-10-08T13:01:16.347-07:00

Another old article, but some might have missed it before due to bizjournals subscription requirements.On the frontlines of researchReolysin only the first virus to undergo clinical trial at Institute for Drug DevelopmentSan Antonio Business Journal - by Sandra Lowe SanchezFriday, September 21, 2007Twice so far, Kenneth Scott has had something most people try to avoid injected into his veins -- a

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-10227627236175073102007-10-04T23:02:00.000-07:002007-10-04T23:09:17.682-07:00

CALGARY, AB, October 4, 2007 --- Ms. Mary Ann Dillahunty, Vice President, Intellectual Property of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at BIO InvestorForum 2007 on Thursday, October 11 at 12 p.m. PT. The conference will be held at the Palace Hotel in San Francisco from October 9-11, 2007. A live audio link to the webcast presentation

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-35685940042699853842007-10-03T17:57:00.000-07:002007-10-03T18:17:09.055-07:00

CALGARY, AB, October 3, 2007 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 15th annual BioPartnering Europe conference in London, U.K. on Tuesday, October 9 at 9 a.m. The conference will be held at the Queen Elizabeth II Conference Centre from October 7-9, 2007.See the full release

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-65388067032214862092007-10-02T00:56:00.000-07:002007-10-03T20:17:37.796-07:00

As we move to the end of the year, Oncolytics Biotech makes good on its promises to deliver good news as it presents today at the National Cancer Research Institute (NCRI) confrence in Birmingham, U.K..The following is an excerpt of somewhat dated interview, but bears listening to as it guides us to what we should expect in late 2007 and early 2008.Interview from wallst.net with Brad Thomas by

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com2tag:blogger.com,1999:blog-4201808194301598766.post-28325084314867687762007-09-28T13:48:00.000-07:002007-09-28T13:51:04.839-07:00

Press ReleaseSource: Oncolytics Biotech Inc.Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical TrialFriday September 28, 2:35 pm ETCALGARY, Sept. 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that an oral presentation covering interim results from a U.K. Phase Ia/Ib

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0tag:blogger.com,1999:blog-4201808194301598766.post-32243521684814149952007-09-28T00:45:00.000-07:002007-10-03T20:20:33.113-07:00

...Oncolytics Chairman, President and CEO, Dr. Brad Thompson, told Knobias on Thursday, "The reovirus works by exploiting a set of mutations in the RAS pathway, a signaling pathway in the cell. Approximately two thirds of all human cancer cells may have mutations along the RAS pathway and could become targets for our REOLYSIN(R) therapy.""Currently, we are testing REOLYSIN in seven Phase I and

Authorhttp://www.blogger.com/profile/06621756564312322012noreply@blogger.com0